Header Logo

Connection

LORETTA NASTOUPIL to Lymphoma, T-Cell

Back to Details
This is a "connection" page, showing publications LORETTA NASTOUPIL has written about Lymphoma, T-Cell.
LORETTA NASTOUPIL
Connection Strength
0.251
Lymphoma, T-Cell
  1. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 01; 105(1):e26-e28.
    View in: PubMed
    Score: 0.136
  2. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758.
    View in: PubMed
    Score: 0.115
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.